Personalized vaccines show promise in extending survival for some brain cancer patients, Dana-Farber study finds

Personalized cancer vaccines are being investigated as a way to make aggressive brain tumors more responsive to immunotherapy, according to new research from the Dana-Farber Cancer Institute.

The study suggests that tailoring vaccines to each patient’s tumor may increase susceptibility to immune-based treatments and could translate into longer survival for a subset of patients.

If confirmed in larger trials, the approach could add a new tool for clinicians treating brain cancers that have historically had limited therapeutic options.

Further clinical testing is planned to validate the early findings and determine which patients are most likely to benefit.